Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the... see more

Recent & Breaking News (NDAQ:PRTA)

Prothena to Report First Quarter 2023 Financial Results on May 4

Business Wire April 27, 2023

Prothena to Participate in 2023 Bank of America Healthcare Conference

Business Wire April 24, 2023

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial

Business Wire April 13, 2023

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Business Wire March 31, 2023

Prothena to Participate in Stifel 2023 Virtual CNS Days

Business Wire March 21, 2023

Prothena to Highlight Next Generation Treatments for Alzheimer's and Parkinson's Disease at the AD/PD 2023 Meeting

Business Wire March 14, 2023

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

Business Wire February 23, 2023

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Business Wire February 16, 2023

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 3, 2023

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer's Disease

Business Wire January 31, 2023

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

Business Wire December 14, 2022

Prothena Announces Proposed Public Offering of Ordinary Shares

Business Wire December 13, 2022

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Business Wire December 12, 2022

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Business Wire November 21, 2022

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

Business Wire November 3, 2022

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

Business Wire November 3, 2022

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

GlobeNewswire October 27, 2022

Prothena to Participate in Upcoming Healthcare Conferences

GlobeNewswire September 1, 2022

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

GlobeNewswire September 1, 2022

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

GlobeNewswire August 8, 2022